You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGalantamine
Accession NumberDB00674  (APRD00206, EXPT01628)
TypeSmall Molecule
GroupsApproved
DescriptionA benzazepine derived from norbelladine. It is found in galanthus and other amaryllidaceae. Galantamine is a cholinesterase inhibitor that has been used to reverse the muscular effects of gallamine triethiodide and tubocurarine, and has been studied as a treatment for Alzheimer's disease and other central nervous system disorders. [PubChem]
Structure
Thumb
Synonyms
(-)-Galanthamine
Galanthamine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-galantamine ERcapsule (extended release)8 mgoralAuro Pharma Inc2014-06-12Not applicableCanada
Auro-galantamine ERcapsule (extended release)16 mgoralAuro Pharma Inc2014-06-12Not applicableCanada
Auro-galantamine ERcapsule (extended release)24 mgoralAuro Pharma Inc2014-06-12Not applicableCanada
Galantamine ERcapsule (extended release)16 mgoralSanis Health Inc2016-01-11Not applicableCanada
Galantamine ERcapsule (extended release)8 mgoralPro Doc Limitee2013-12-03Not applicableCanada
Galantamine ERcapsule (extended release)24 mgoralSanis Health Inc2016-01-11Not applicableCanada
Galantamine ERcapsule (extended release)16 mgoralPro Doc Limitee2013-12-03Not applicableCanada
Galantamine ERcapsule (extended release)24 mgoralPro Doc Limitee2013-12-03Not applicableCanada
Galantamine ERcapsule (extended release)8 mgoralSanis Health Inc2016-01-11Not applicableCanada
Galantamine Hydrobromidetablet, film coated4 mg/1oralYabao Pharmaceutical Co., Ltd. Beijing2001-03-01Not applicableUs
Galantamine Hydrobromidetablet, film coated4 mg/1oralPatriot Pharmaceuticals, LLC2001-02-28Not applicableUs
Galantamine Hydrobromidecapsule, extended release16 mg/1oralPatriot Pharmaceuticals, LLC2004-12-22Not applicableUs
Galantamine Hydrobromidetablet, film coated8 mg/1oralYabao Pharmaceutical Co., Ltd. Beijing2001-03-01Not applicableUs
Galantamine Hydrobromidetablet, film coated8 mg/1oralPatriot Pharmaceuticals, LLC2001-02-28Not applicableUs
Galantamine Hydrobromidecapsule, extended release24 mg/1oralPatriot Pharmaceuticals, LLC2004-12-22Not applicableUs
Galantamine Hydrobromidetablet, film coated12 mg/1oralYabao Pharmaceutical Co., Ltd. Beijing2001-03-01Not applicableUs
Galantamine Hydrobromidetablet, film coated12 mg/1oralPatriot Pharmaceuticals, LLC2001-02-28Not applicableUs
Galantamine Hydrobromidetablet, film coated12 mg/1oralAvera Mc Kennan Hospital2015-09-02Not applicableUs
Galantamine Hydrobromidecapsule, extended release8 mg/1oralPatriot Pharmaceuticals, LLC2004-12-22Not applicableUs
Ipg-galantamine ERcapsule (extended release)8 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-galantamine ERcapsule (extended release)16 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-galantamine ERcapsule (extended release)24 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Mar-galantamine ERcapsule (extended release)8 mgoralMarcan Pharmaceuticals Inc2015-02-25Not applicableCanada
Mar-galantamine ERcapsule (extended release)16 mgoralMarcan Pharmaceuticals Inc2015-02-25Not applicableCanada
Mar-galantamine ERcapsule (extended release)24 mgoralMarcan Pharmaceuticals Inc2015-03-25Not applicableCanada
Mylan-galantamine ERcapsule (extended release)16 mgoralMylan Pharmaceuticals Ulc2010-11-12Not applicableCanada
Mylan-galantamine ERcapsule (extended release)24 mgoralMylan Pharmaceuticals Ulc2010-11-12Not applicableCanada
Mylan-galantamine ERcapsule (extended release)8 mgoralMylan Pharmaceuticals Ulc2010-11-12Not applicableCanada
Pat-galantamine ERcapsule (extended release)8 mgoralPatriot A Division Of Janssen Inc2011-01-05Not applicableCanada
Pat-galantamine ERcapsule (extended release)16 mgoralPatriot A Division Of Janssen Inc2011-01-05Not applicableCanada
Pat-galantamine ERcapsule (extended release)24 mgoralPatriot A Division Of Janssen Inc2011-01-05Not applicableCanada
Pendo-galantamine ERcapsule (extended release)8 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PMS-galantaminetablet12 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-galantaminetablet4 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-galantaminetablet8 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-galantamine ERcapsule (extended release)8 mgoralPharmascience Inc2013-06-13Not applicableCanada
PMS-galantamine ERcapsule (extended release)16 mgoralPharmascience Inc2013-06-13Not applicableCanada
PMS-galantamine ERcapsule (extended release)24 mgoralPharmascience Inc2013-06-13Not applicableCanada
Ratio-galantaminetablet12 mgoralRatiopharm Inc Division Of Teva Canada LimitedNot applicableNot applicableCanada
Ratio-galantaminetablet4 mgoralRatiopharm Inc Division Of Teva Canada LimitedNot applicableNot applicableCanada
Ratio-galantaminetablet8 mgoralRatiopharm Inc Division Of Teva Canada LimitedNot applicableNot applicableCanada
Razadynetablet, film coated12 mg/1oralRebel Distributors Corp2001-02-28Not applicableUs
Razadynetablet, film coated4 mg/1oralJanssen Pharmaceuticals, Inc.2001-03-01Not applicableUs
Razadynecapsule, extended release8 mg/1oralJanssen Pharmaceuticals, Inc.2004-12-24Not applicableUs
Razadynetablet, film coated8 mg/1oralJanssen Pharmaceuticals, Inc.2001-03-01Not applicableUs
Razadynecapsule, extended release16 mg/1oralJanssen Pharmaceuticals, Inc.2004-12-24Not applicableUs
Razadynetablet, film coated12 mg/1oralJanssen Pharmaceuticals, Inc.2001-03-01Not applicableUs
Razadynetablet, film coated8 mg/1oralRebel Distributors Corp2001-02-28Not applicableUs
Razadynecapsule, extended release24 mg/1oralJanssen Pharmaceuticals, Inc.2004-12-24Not applicableUs
Razadynesolution4 mg/mLoralJanssen Pharmaceuticals, Inc.2001-06-22Not applicableUs
Reminyl -(12mg)tablet12 mgoralJanssen Inc2001-08-102009-08-05Canada
Reminyl -(4mg)tablet4 mgoralJanssen Inc2001-08-082009-08-05Canada
Reminyl -(8mg)tablet8 mgoralJanssen Inc2001-08-082009-08-05Canada
Reminyl ERcapsule (extended release)8 mgoralJanssen Inc2005-04-29Not applicableCanada
Reminyl ERcapsule (extended release)16 mgoralJanssen Inc2005-04-29Not applicableCanada
Reminyl ERcapsule (extended release)24 mgoralJanssen Inc2005-04-29Not applicableCanada
Sandoz Galantamine ERcapsule (extended release)8 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Galantamine ERcapsule (extended release)16 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Galantamine ERcapsule (extended release)24 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Teva-galantamine ERcapsule (extended release)24 mgoralTeva Canada Limited2012-01-06Not applicableCanada
Teva-galantamine ERcapsule (extended release)8 mgoralTeva Canada Limited2012-01-06Not applicableCanada
Teva-galantamine ERcapsule (extended release)16 mgoralTeva Canada Limited2012-01-06Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-galantaminetablet4 mgoralApotex IncNot applicableNot applicableCanada
Apo-galantaminetablet8 mgoralApotex IncNot applicableNot applicableCanada
Apo-galantaminetablet12 mgoralApotex IncNot applicableNot applicableCanada
Galantaminetablet, film coated8 mg/1oralAurobindo Pharma Limited2011-03-29Not applicableUs
Galantaminetablet, film coated4 mg/1oralMylan Institutional Inc.2009-11-09Not applicableUs
Galantaminetablet, film coated12 mg/1oralApotex Corp.2012-11-05Not applicableUs
Galantaminecapsule, extended release8 mg/1oralBarr Laboratories Inc.2008-10-14Not applicableUs
Galantaminetablet, film coated8 mg/1oralCitron Pharma LLC2011-03-29Not applicableUs
Galantaminetablet, film coated8 mg/1oralBarr Laboratories Inc.2008-08-28Not applicableUs
Galantaminetablet, film coated12 mg/1oralZydus Pharmaceuticals (USA) Inc.2011-10-10Not applicableUs
Galantaminetablet, film coated4 mg/1oralMylan Pharmaceuticals Inc.2008-08-29Not applicableUs
Galantaminetablet, film coated8 mg/1oralCadila Healthcare Limited2011-10-10Not applicableUs
Galantaminetablet, film coated12 mg/1oralAurobindo Pharma Limited2011-03-29Not applicableUs
Galantaminetablet, film coated8 mg/1oralMylan Institutional Inc.2009-11-09Not applicableUs
Galantaminetablet, film coated8 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-03-29Not applicableUs
Galantaminecapsule, extended release16 mg/1oralBarr Laboratories Inc.2008-10-15Not applicableUs
Galantaminetablet, film coated4 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-05-29Not applicableUs
Galantaminetablet, film coated12 mg/1oralCitron Pharma LLC2011-03-29Not applicableUs
Galantaminetablet, film coated12 mg/1oralBarr Laboratories Inc.2008-08-28Not applicableUs
Galantaminetablet, film coated8 mg/1oralMylan Pharmaceuticals Inc.2008-08-29Not applicableUs
Galantaminetablet, film coated12 mg/1oralCadila Healthcare Limited2011-10-10Not applicableUs
Galantaminetablet, film coated4 mg/1oralZydus Pharmaceuticals (USA) Inc.2011-10-10Not applicableUs
Galantaminetablet, film coated12 mg/1oralMylan Institutional Inc.2009-11-09Not applicableUs
Galantaminetablet, film coated4 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-03-29Not applicableUs
Galantaminecapsule, extended release24 mg/1oralBarr Laboratories Inc.2008-10-15Not applicableUs
Galantaminetablet, film coated8 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-05-29Not applicableUs
Galantaminetablet, film coated4 mg/1oralApotex Corp.2012-11-05Not applicableUs
Galantaminetablet, film coated12 mg/1oralMylan Pharmaceuticals Inc.2008-08-29Not applicableUs
Galantaminetablet, film coated4 mg/1oralAurobindo Pharma Limited2011-03-29Not applicableUs
Galantaminetablet, film coated4 mg/1oralBarr Laboratories Inc.2008-08-28Not applicableUs
Galantaminetablet, film coated8 mg/1oralZydus Pharmaceuticals (USA) Inc.2011-10-10Not applicableUs
Galantaminetablet, film coated4 mg/1oralCitron Pharma LLC2011-03-29Not applicableUs
Galantaminetablet, film coated4 mg/1oralCadila Healthcare Limited2011-10-10Not applicableUs
Galantaminetablet, film coated4 mg/1oralAmerican Health Packaging2014-06-23Not applicableUs
Galantaminetablet, film coated12 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-05-29Not applicableUs
Galantaminetablet, film coated8 mg/1oralApotex Corp.2012-11-05Not applicableUs
Galantamine Hydrobromidecapsule, extended release8 mg/1oralMylan Pharmaceuticals Inc.2011-01-24Not applicableUs
Galantamine Hydrobromidesolution4 mg/mLoralRoxane Laboratories, Inc2009-08-14Not applicableUs
Galantamine Hydrobromidecapsule, extended release24 mg/1oralWatson Laboratories, Inc.2009-12-15Not applicableUs
Galantamine Hydrobromidecapsule, extended release8 mg/1oralSun Pharma Global FZE2011-02-09Not applicableUs
Galantamine Hydrobromidecapsule, extended release16 mg/1oralMylan Pharmaceuticals Inc.2011-01-24Not applicableUs
Galantamine Hydrobromidecapsule, extended release8 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-05-27Not applicableUs
Galantamine Hydrobromidecapsule, extended release16 mg/1oralSun Pharma Global FZE2011-02-09Not applicableUs
Galantamine Hydrobromidecapsule, extended release24 mg/1oralMylan Pharmaceuticals Inc.2011-01-24Not applicableUs
Galantamine Hydrobromidecapsule, extended release16 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-05-27Not applicableUs
Galantamine Hydrobromidecapsule, extended release8 mg/1oralWatson Laboratories, Inc.2009-12-15Not applicableUs
Galantamine Hydrobromidecapsule, extended release24 mg/1oralSun Pharma Global FZE2011-02-09Not applicableUs
Galantamine Hydrobromidecapsule, extended release24 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-05-27Not applicableUs
Galantamine Hydrobromidecapsule, extended release16 mg/1oralWatson Laboratories, Inc.2009-12-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LycoremineNot Available
NivalinNot Available
ReminylNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Galantamine hydrobromide
Thumb
  • InChI Key: QORVDGQLPPAFRS-XPSHAMGMSA-N
  • Monoisotopic Mass: 367.078306222
  • Average Mass: 368.265
DBSALT000316
Categories
UNII0D3Q044KCA
CAS number357-70-0
WeightAverage: 287.3535
Monoisotopic: 287.152143543
Chemical FormulaC17H21NO3
InChI KeyInChIKey=ASUTZQLVASHGKV-JDFRZJQESA-N
InChI
InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
IUPAC Name
(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol
SMILES
[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as galanthamine-type amaryllidaceae alkaloids. These are amaryllidaceae alkaloids with a structure characterized a tetracyclic skeleton with two ortho aromatic protons in ring A.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassAmaryllidaceae alkaloids
Sub ClassGalanthamine-type amaryllidaceae alkaloids
Direct ParentGalanthamine-type amaryllidaceae alkaloids
Alternative Parents
Substituents
  • Galanthamine-type amaryllidaceae alkaloid
  • Benzazepine
  • Benzofuran
  • Anisole
  • Aralkylamine
  • Azepine
  • Alkyl aryl ether
  • Benzenoid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of mild to moderate dementia of the Alzheimer's type. Has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for Alzheimer's disease.
PharmacodynamicsGalantamine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. It is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Galantamine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, Galantamine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that Galantamine alters the course of the underlying dementing process.
Mechanism of actionGalantamine is a phenanthrene alkaloid and a reversible, competitive acetylcholinesterase inhibitor. It is not structurally related to other acetylcholinesterase inhibitors. Galantamine's proposed mechanism of action involves the reversible inhibition of acetylcholinesterase, which prevents the hydrolysis of acetycholine, leading to an increased concentration of acetylcholine at cholinergic synapses. Galantamine also binds allosterically with nicotinic acetylcholine receptors and may possibly potentiate the action of agonists (such as acetylcholine) at these receptors.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 175 L
Protein binding18%
MetabolismNot Available
Route of eliminationGalantamine is metabolized by hepatic cytochrome P450 enzymes, glucuronidated, and excreted unchanged in the urine.
Half life7 hours
Clearance
  • 300 mL/min [After IV. or oral administration]
ToxicityLD50=75 mg/kg (rat)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9959
Caco-2 permeable+0.8259
P-glycoprotein substrateSubstrate0.8976
P-glycoprotein inhibitor IInhibitor0.6069
P-glycoprotein inhibitor IINon-inhibitor0.9443
Renal organic cation transporterInhibitor0.5728
CYP450 2C9 substrateNon-substrate0.8072
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.5414
CYP450 2C19 inhibitorNon-inhibitor0.8301
CYP450 3A4 inhibitorNon-inhibitor0.8832
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9439
Ames testNon AMES toxic0.7995
CarcinogenicityNon-carcinogens0.9055
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7790 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8023
hERG inhibition (predictor II)Non-inhibitor0.7424
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Barr laboratories inc
  • Impax laboratories inc
  • Watson laboratories inc
  • Ortho mcneil janssen pharmaceuticals inc
  • Roxane laboratories inc
  • Ortho mcneil janssen pharmaceutical inc
  • Actavis elizabeth llc
  • Beijing yabao biopharmaceutical co ltd
  • Dr reddys laboratories ltd
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedoral12 mg/1
Tablet, film coatedoral4 mg/1
Tablet, film coatedoral8 mg/1
Capsule, extended releaseoral16 mg/1
Capsule, extended releaseoral24 mg/1
Capsule, extended releaseoral8 mg/1
Solutionoral4 mg/mL
Tabletoral12 mg
Tabletoral4 mg
Tabletoral8 mg
Capsule (extended release)oral16 mg
Capsule (extended release)oral24 mg
Capsule (extended release)oral8 mg
Prices
Unit descriptionCostUnit
Galantamine Hydrobromide 30 16 mg 24 Hour Capsule Bottle198.58USD bottle
Galantamine Hydrobromide 30 8 mg 24 Hour Capsule Bottle198.58USD bottle
Razadyne 12 mg tablet8.3USD tablet
Razadyne 4 mg tablet5.36USD tablet
Razadyne 8 mg tablet3.66USD tablet
Galantamine hbr 12 mg tablet3.18USD tablet
Galantamine hbr 4 mg tablet3.18USD tablet
Galantamine hbr 8 mg tablet3.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2310926 No2001-11-202017-06-06Canada
CA2358062 No2006-12-192019-12-20Canada
US6099863 No1997-06-062017-06-06Us
US6358527 No1997-06-062017-06-06Us
US7160559 No1999-12-202019-12-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point269-270 °C (HBr salt)Not Available
water solubility10 mg/mL (HBr salt)Not Available
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.7 mg/mLALOGPS
logP1.39ALOGPS
logP1.16ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)14.81ChemAxon
pKa (Strongest Basic)8.91ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.93 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.3 m3·mol-1ChemAxon
Polarizability31.4 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-000l-5980000000-928ad889466b6a2b3827View in MoNA
References
Synthesis Reference

Vijaya Bolugoddu, Sanjay Shukla, Mukunda Jambula, Rajeshwar Sagyam, Ramchandra Pingili, Ananda Thirunavakarasu, “Preparation of (-)-galantamine hydrobromide.” U.S. Patent US20060009640, issued January 12, 2006.

US20060009640
General References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. [PubMed:10606746 ]
  3. Woodruff-Pak DS, Vogel RW 3rd, Wenk GL: Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2089-94. Epub 2001 Feb 6. [PubMed:11172080 ]
  4. Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. [PubMed:16437532 ]
  5. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  6. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
External Links
ATC CodesN06DA04
AHFS Codes
  • 12:04.00
PDB EntriesNot Available
FDA labelDownload (278 KB)
MSDSDownload (28.4 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Galantamine.
AbirateroneThe metabolism of Galantamine can be decreased when combined with Abiraterone.
AcebutololGalantamine may increase the bradycardic activities of Acebutolol.
AcetylcholineThe risk or severity of adverse effects can be increased when Galantamine is combined with Acetylcholine.
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Galantamine.
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Galantamine.
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Galantamine.
AlprenololGalantamine may increase the bradycardic activities of Alprenolol.
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Galantamine.
AmiodaroneGalantamine may increase the bradycardic activities of Amiodarone.
AmoxapineThe metabolism of Galantamine can be decreased when combined with Amoxapine.
AnagrelideGalantamine may increase the QTc-prolonging activities of Anagrelide.
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Galantamine.
AprepitantThe serum concentration of Galantamine can be increased when it is combined with Aprepitant.
ArecolineThe risk or severity of adverse effects can be increased when Galantamine is combined with Arecoline.
ArotinololGalantamine may increase the bradycardic activities of Arotinolol.
Arsenic trioxideGalantamine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherGalantamine may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Galantamine can be decreased when combined with Artemether.
AsenapineGalantamine may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe metabolism of Galantamine can be decreased when combined with Atazanavir.
AtenololGalantamine may increase the bradycardic activities of Atenolol.
AtomoxetineThe metabolism of Galantamine can be decreased when combined with Atomoxetine.
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Galantamine.
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Galantamine.
AzithromycinGalantamine may increase the QTc-prolonging activities of Azithromycin.
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Galantamine.
BedaquilineGalantamine may increase the QTc-prolonging activities of Bedaquiline.
BefunololGalantamine may increase the bradycardic activities of Befunolol.
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Galantamine.
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Galantamine.
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Galantamine.
BeractantGalantamine may increase the bradycardic activities of Beractant.
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Galantamine.
BetaxololGalantamine may increase the bradycardic activities of Betaxolol.
BethanecholThe risk or severity of adverse effects can be increased when Galantamine is combined with Bethanechol.
BevantololGalantamine may increase the bradycardic activities of Bevantolol.
BexaroteneThe serum concentration of Galantamine can be decreased when it is combined with Bexarotene.
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Galantamine.
BisoprololGalantamine may increase the bradycardic activities of Bisoprolol.
BoceprevirThe metabolism of Galantamine can be decreased when combined with Boceprevir.
BopindololGalantamine may increase the bradycardic activities of Bopindolol.
BortezomibThe metabolism of Galantamine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Galantamine can be decreased when it is combined with Bosentan.
BretyliumBretylium may increase the bradycardic activities of Galantamine.
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Galantamine.
BufuralolGalantamine may increase the bradycardic activities of Bufuralol.
BupranololGalantamine may increase the bradycardic activities of Bupranolol.
BupropionThe metabolism of Galantamine can be decreased when combined with Bupropion.
CalfactantGalantamine may increase the bradycardic activities of Calfactant.
CarbacholThe risk or severity of adverse effects can be increased when Galantamine is combined with Carbachol.
CarbamazepineThe metabolism of Galantamine can be increased when combined with Carbamazepine.
CarteololGalantamine may increase the bradycardic activities of Carteolol.
CarvedilolGalantamine may increase the bradycardic activities of Carvedilol.
CelecoxibThe metabolism of Galantamine can be decreased when combined with Celecoxib.
CeliprololGalantamine may increase the bradycardic activities of Celiprolol.
CeritinibGalantamine may increase the bradycardic activities of Ceritinib.
CeritinibThe serum concentration of Galantamine can be increased when it is combined with Ceritinib.
CevimelineThe risk or severity of adverse effects can be increased when Galantamine is combined with Cevimeline.
ChloroquineGalantamine may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Galantamine can be decreased when combined with Chloroquine.
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Galantamine.
ChlorpromazineGalantamine may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe metabolism of Galantamine can be decreased when combined with Chlorpromazine.
CholecalciferolThe metabolism of Galantamine can be decreased when combined with Cholecalciferol.
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Galantamine.
CimetidineThe metabolism of Galantamine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Galantamine can be decreased when combined with Cinacalcet.
CiprofloxacinGalantamine may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideGalantamine may increase the QTc-prolonging activities of Cisapride.
CitalopramThe metabolism of Galantamine can be decreased when combined with Citalopram.
CitalopramGalantamine may increase the QTc-prolonging activities of Citalopram.
ClarithromycinGalantamine may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Galantamine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Galantamine can be decreased when combined with Clemastine.
ClobazamThe metabolism of Galantamine can be decreased when combined with Clobazam.
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Galantamine.
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Galantamine.
ClomipramineThe metabolism of Galantamine can be decreased when combined with Clomipramine.
ClonidineClonidine may increase the bradycardic activities of Galantamine.
ClotrimazoleThe metabolism of Galantamine can be decreased when combined with Clotrimazole.
ClozapineGalantamine may increase the QTc-prolonging activities of Clozapine.
ClozapineThe metabolism of Galantamine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Galantamine can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Galantamine can be decreased when combined with Cocaine.
ConivaptanThe serum concentration of Galantamine can be increased when it is combined with Conivaptan.
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Galantamine.
CrizotinibGalantamine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Galantamine can be decreased when combined with Crizotinib.
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Galantamine.
CyclosporineThe metabolism of Galantamine can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Galantamine can be decreased when it is combined with Dabrafenib.
DapoxetineThe metabolism of Galantamine can be decreased when combined with Dapoxetine.
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Galantamine.
DarifenacinThe metabolism of Galantamine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Galantamine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Galantamine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Galantamine can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Dehydroepiandrosterone is combined with Galantamine.
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Galantamine.
DelavirdineThe metabolism of Galantamine can be decreased when combined with Delavirdine.
DesipramineThe metabolism of Galantamine can be decreased when combined with Desipramine.
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Galantamine.
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Galantamine.
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Galantamine.
DexamethasoneThe serum concentration of Galantamine can be decreased when it is combined with Dexamethasone.
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Galantamine.
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Galantamine.
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Galantamine.
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Galantamine.
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Galantamine.
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Galantamine.
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Galantamine.
DigoxinDigoxin may increase the bradycardic activities of Galantamine.
DihydroergotamineThe metabolism of Galantamine can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Galantamine can be decreased when combined with Diltiazem.
DiltiazemGalantamine may increase the bradycardic activities of Diltiazem.
DiphenhydramineThe metabolism of Galantamine can be decreased when combined with Diphenhydramine.
DipyridamoleThe therapeutic efficacy of Galantamine can be decreased when used in combination with Dipyridamole.
DisopyramideGalantamine may increase the QTc-prolonging activities of Disopyramide.
DofetilideGalantamine may increase the QTc-prolonging activities of Dofetilide.
DolasetronGalantamine may increase the QTc-prolonging activities of Dolasetron.
DomperidoneGalantamine may increase the QTc-prolonging activities of Domperidone.
DonepezilGalantamine may increase the bradycardic activities of Donepezil.
DoxycyclineThe metabolism of Galantamine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Galantamine can be decreased when combined with Dronedarone.
DronedaroneGalantamine may increase the bradycardic activities of Dronedarone.
DroperidolGalantamine may increase the QTc-prolonging activities of Droperidol.
DuloxetineThe metabolism of Galantamine can be decreased when combined with Duloxetine.
EfavirenzThe serum concentration of Galantamine can be decreased when it is combined with Efavirenz.
EliglustatGalantamine may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Galantamine can be decreased when combined with Eliglustat.
EnzalutamideThe serum concentration of Galantamine can be decreased when it is combined with Enzalutamide.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Galantamine is combined with EPIBATIDINE.
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Galantamine.
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Galantamine.
ErythromycinGalantamine may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Galantamine can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Galantamine can be decreased when combined with Escitalopram.
EscitalopramGalantamine may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Galantamine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololGalantamine may increase the bradycardic activities of Esmolol.
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Galantamine.
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Galantamine.
EtoperidoneThe metabolism of Galantamine can be decreased when combined with Etoperidone.
EtravirineThe serum concentration of Galantamine can be decreased when it is combined with Etravirine.
FenfluramineThe metabolism of Galantamine can be decreased when combined with Fenfluramine.
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Galantamine.
FingolimodGalantamine may increase the bradycardic activities of Fingolimod.
FlecainideGalantamine may increase the QTc-prolonging activities of Flecainide.
FluconazoleThe metabolism of Galantamine can be decreased when combined with Fluconazole.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Galantamine.
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Galantamine.
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Galantamine.
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Galantamine.
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Galantamine.
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Galantamine.
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Galantamine.
FluoxetineThe metabolism of Galantamine can be decreased when combined with Fluoxetine.
FluoxetineGalantamine may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolGalantamine may increase the QTc-prolonging activities of Flupentixol.
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Galantamine.
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Galantamine.
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Galantamine.
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Galantamine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Galantamine.
FluvoxamineThe metabolism of Galantamine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Galantamine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Galantamine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Galantamine can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Galantamine can be increased when it is combined with Fusidic Acid.
Gadobenic acidGalantamine may increase the QTc-prolonging activities of Gadobenic acid.
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Galantamine.
GemifloxacinGalantamine may increase the QTc-prolonging activities of Gemifloxacin.
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Galantamine.
GoserelinGalantamine may increase the QTc-prolonging activities of Goserelin.
GranisetronGalantamine may increase the QTc-prolonging activities of Granisetron.
GTS-21The risk or severity of adverse effects can be increased when Galantamine is combined with GTS-21.
GuanfacineGalantamine may increase the bradycardic activities of Guanfacine.
HaloperidolGalantamine may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe metabolism of Galantamine can be decreased when combined with Haloperidol.
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Galantamine.
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Galantamine.
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Galantamine.
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Galantamine.
IbutilideGalantamine may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Galantamine can be increased when it is combined with Idelalisib.
IloperidoneGalantamine may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Galantamine can be decreased when combined with Imatinib.
ImipramineThe metabolism of Galantamine can be decreased when combined with Imipramine.
IndalpineThe metabolism of Galantamine can be decreased when combined with Indalpine.
IndenololGalantamine may increase the bradycardic activities of Indenolol.
IndinavirThe metabolism of Galantamine can be decreased when combined with Indinavir.
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Galantamine.
IsavuconazoniumThe metabolism of Galantamine can be decreased when combined with Isavuconazonium.
IsoniazidThe metabolism of Galantamine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Galantamine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Galantamine can be decreased when combined with Itraconazole.
IvabradineGalantamine may increase the bradycardic activities of Ivabradine.
IvacaftorThe serum concentration of Galantamine can be increased when it is combined with Ivacaftor.
KetoconazoleThe metabolism of Galantamine can be decreased when combined with Ketoconazole.
LabetalolGalantamine may increase the bradycardic activities of Labetalol.
LacosamideGalantamine may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LanreotideGalantamine may increase the bradycardic activities of Lanreotide.
LenvatinibGalantamine may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideGalantamine may increase the QTc-prolonging activities of Leuprolide.
LevobunololGalantamine may increase the bradycardic activities of Levobunolol.
LevofloxacinGalantamine may increase the QTc-prolonging activities of Levofloxacin.
LevomilnacipranThe metabolism of Galantamine can be decreased when combined with Levomilnacipran.
LobelineThe risk or severity of adverse effects can be increased when Galantamine is combined with Lobeline.
LopinavirThe metabolism of Galantamine can be decreased when combined with Lopinavir.
LopinavirGalantamine may increase the QTc-prolonging activities of Lopinavir.
LorcaserinThe metabolism of Galantamine can be decreased when combined with Lorcaserin.
LovastatinThe metabolism of Galantamine can be decreased when combined with Lovastatin.
Lu AA21004The metabolism of Galantamine can be decreased when combined with Lu AA21004.
LucinactantGalantamine may increase the bradycardic activities of Lucinactant.
LuliconazoleThe serum concentration of Galantamine can be increased when it is combined with Luliconazole.
LumefantrineGalantamine may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Galantamine can be decreased when combined with Lumefantrine.
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Galantamine.
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Galantamine.
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Galantamine.
MethacholineThe risk or severity of adverse effects can be increased when Galantamine is combined with Methacholine.
MethadoneGalantamine may increase the QTc-prolonging activities of Methadone.
MethadoneThe metabolism of Galantamine can be decreased when combined with Methadone.
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Galantamine.
MethotrimeprazineThe metabolism of Galantamine can be decreased when combined with Methotrimeprazine.
MethyldopaGalantamine may increase the bradycardic activities of Methyldopa.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Galantamine.
MetipranololGalantamine may increase the bradycardic activities of Metipranolol.
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Galantamine.
MetoprololGalantamine may increase the bradycardic activities of Metoprolol.
MifepristoneThe metabolism of Galantamine can be decreased when combined with Mifepristone.
MifepristoneGalantamine may increase the QTc-prolonging activities of Mifepristone.
MilnacipranThe metabolism of Galantamine can be decreased when combined with Milnacipran.
MirabegronThe metabolism of Galantamine can be decreased when combined with Mirabegron.
MitotaneThe serum concentration of Galantamine can be decreased when it is combined with Mitotane.
MivacuriumGalantamine may decrease the neuromuscular blocking activities of Mivacurium.
ModafinilThe serum concentration of Galantamine can be decreased when it is combined with Modafinil.
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Galantamine.
MoxifloxacinGalantamine may increase the QTc-prolonging activities of Moxifloxacin.
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with Galantamine.
NadololGalantamine may increase the bradycardic activities of Nadolol.
NafcillinThe serum concentration of Galantamine can be decreased when it is combined with Nafcillin.
NebivololGalantamine may increase the bradycardic activities of Nebivolol.
NefazodoneThe metabolism of Galantamine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Galantamine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Galantamine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Galantamine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Galantamine can be decreased when combined with Nicardipine.
NicotineThe risk or severity of adverse effects can be increased when Galantamine is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Galantamine is combined with Nicotine bitartrate.
NilotinibThe metabolism of Galantamine can be decreased when combined with Nilotinib.
NilotinibGalantamine may increase the QTc-prolonging activities of Nilotinib.
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with Galantamine.
OctreotideOctreotide may increase the bradycardic activities of Galantamine.
OfloxacinGalantamine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe metabolism of Galantamine can be decreased when combined with Olanzapine.
OlaparibThe metabolism of Galantamine can be decreased when combined with Olaparib.
OndansetronGalantamine may increase the QTc-prolonging activities of Ondansetron.
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Galantamine.
OsimertinibThe serum concentration of Galantamine can be increased when it is combined with Osimertinib.
OxprenololGalantamine may increase the bradycardic activities of Oxprenolol.
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Galantamine.
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Galantamine.
PalbociclibThe serum concentration of Galantamine can be increased when it is combined with Palbociclib.
PaliperidoneGalantamine may increase the QTc-prolonging activities of Paliperidone.
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Galantamine.
PanobinostatGalantamine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Galantamine can be decreased when combined with Panobinostat.
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Galantamine.
ParoxetineThe metabolism of Galantamine can be decreased when combined with Paroxetine.
PasireotideGalantamine may increase the bradycardic activities of Pasireotide.
PazopanibGalantamine may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Galantamine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololGalantamine may increase the bradycardic activities of Penbutolol.
PentamidineGalantamine may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe metabolism of Galantamine can be increased when combined with Pentobarbital.
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Galantamine.
PerflutrenGalantamine may increase the QTc-prolonging activities of Perflutren.
PhenobarbitalThe metabolism of Galantamine can be increased when combined with Phenobarbital.
PhenytoinThe metabolism of Galantamine can be increased when combined with Phenytoin.
PilocarpineThe risk or severity of adverse effects can be increased when Galantamine is combined with Pilocarpine.
PimozideGalantamine may increase the QTc-prolonging activities of Pimozide.
PindololGalantamine may increase the bradycardic activities of Pindolol.
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Galantamine.
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Galantamine.
Poractant alfaGalantamine may increase the bradycardic activities of Poractant alfa.
PosaconazoleThe metabolism of Galantamine can be decreased when combined with Posaconazole.
PractololGalantamine may increase the bradycardic activities of Practolol.
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Galantamine.
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Galantamine.
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Galantamine.
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Galantamine.
PrimaquineGalantamine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Galantamine can be increased when combined with Primidone.
ProcainamideGalantamine may increase the QTc-prolonging activities of Procainamide.
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Galantamine.
PromazineGalantamine may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Galantamine can be decreased when combined with Promazine.
PropafenoneGalantamine may increase the QTc-prolonging activities of Propafenone.
PropafenonePropafenone may increase the bradycardic activities of Galantamine.
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Galantamine.
PropranololGalantamine may increase the bradycardic activities of Propranolol.
QuetiapineGalantamine may increase the QTc-prolonging activities of Quetiapine.
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Galantamine.
QuinidineThe metabolism of Galantamine can be decreased when combined with Quinidine.
QuinineGalantamine may increase the QTc-prolonging activities of Quinine.
QuinineThe metabolism of Galantamine can be decreased when combined with Quinine.
RanolazineThe metabolism of Galantamine can be decreased when combined with Ranolazine.
RapacuroniumGalantamine may decrease the neuromuscular blocking activities of Rapacuronium.
RifabutinThe metabolism of Galantamine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Galantamine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Galantamine can be increased when combined with Rifapentine.
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Galantamine.
RitonavirThe metabolism of Galantamine can be decreased when combined with Ritonavir.
RivastigmineGalantamine may increase the bradycardic activities of Rivastigmine.
RolapitantThe metabolism of Galantamine can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Galantamine can be decreased when combined with Ropinirole.
RuxolitinibRuxolitinib may increase the bradycardic activities of Galantamine.
SaquinavirGalantamine may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Galantamine can be decreased when combined with Saquinavir.
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Galantamine.
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Galantamine.
SertralineThe metabolism of Galantamine can be decreased when combined with Sertraline.
SildenafilThe metabolism of Galantamine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Galantamine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Galantamine can be increased when it is combined with Simeprevir.
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Galantamine.
SotalolGalantamine may increase the bradycardic activities of Sotalol.
St. John's WortThe serum concentration of Galantamine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Galantamine can be increased when it is combined with Stiripentol.
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Galantamine.
SufentanilGalantamine may increase the bradycardic activities of Sufentanil.
SulfisoxazoleGalantamine may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Galantamine can be decreased when combined with Sulfisoxazole.
TelaprevirThe metabolism of Galantamine can be decreased when combined with Telaprevir.
TelavancinGalantamine may increase the QTc-prolonging activities of Telavancin.
TelithromycinGalantamine may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Galantamine can be decreased when combined with Telithromycin.
TerbinafineThe metabolism of Galantamine can be decreased when combined with Terbinafine.
TetrabenazineGalantamine may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazineGalantamine may increase the QTc-prolonging activities of Thioridazine.
ThioridazineThe metabolism of Galantamine can be decreased when combined with Thioridazine.
TiclopidineThe metabolism of Galantamine can be decreased when combined with Ticlopidine.
TimololGalantamine may increase the bradycardic activities of Timolol.
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Galantamine.
TipranavirThe metabolism of Galantamine can be decreased when combined with Tipranavir.
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Galantamine.
TizanidineGalantamine may increase the bradycardic activities of Tizanidine.
TocilizumabThe serum concentration of Galantamine can be decreased when it is combined with Tocilizumab.
TofacitinibTofacitinib may increase the bradycardic activities of Galantamine.
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Galantamine.
ToremifeneGalantamine may increase the QTc-prolonging activities of Toremifene.
TranylcypromineThe metabolism of Galantamine can be decreased when combined with Tranylcypromine.
TrazodoneThe metabolism of Galantamine can be decreased when combined with Trazodone.
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Galantamine.
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Galantamine.
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Galantamine.
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Galantamine.
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Galantamine.
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Galantamine.
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Galantamine.
VandetanibGalantamine may increase the QTc-prolonging activities of Vandetanib.
VareniclineThe risk or severity of adverse effects can be increased when Galantamine is combined with Varenicline.
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Galantamine.
VemurafenibGalantamine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Galantamine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Galantamine can be decreased when combined with Verapamil.
VerapamilGalantamine may increase the bradycardic activities of Verapamil.
VilazodoneThe metabolism of Galantamine can be decreased when combined with Vilazodone.
VoriconazoleThe metabolism of Galantamine can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Galantamine can be decreased when combined with Vortioxetine.
ZimelidineThe metabolism of Galantamine can be decreased when combined with Zimelidine.
ZiprasidoneThe metabolism of Galantamine can be decreased when combined with Ziprasidone.
ZiprasidoneGalantamine may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolGalantamine may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine hydrolase activity
Specific Function:
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name:
ACHE
Uniprot ID:
P22303
Molecular Weight:
67795.525 Da
References
  1. Tonkopii VD, Prozorovskii VB, Suslova IM: [Interaction of reversible inhibitors with the catalytic centers and allosteric sites of cholinesterases]. Biull Eksp Biol Med. 1976 Aug;82(8):947-50. [PubMed:1026294 ]
  2. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. [PubMed:10606746 ]
  3. Guillou C, Mary A, Renko DZ, Gras E, Thal C: Potent acetylcholinesterase inhibitors: design, synthesis and structure-activity relationships of alkylene linked bis-galanthamine and galanthamine-galanthaminium salts. Bioorg Med Chem Lett. 2000 Apr 3;10(7):637-9. [PubMed:10762042 ]
  4. Blesa R: Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:28-34. [PubMed:10971049 ]
  5. Stahl SM: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. J Clin Psychiatry. 2000 Oct;61(10):710-1. [PubMed:11078030 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  8. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  9. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  10. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  11. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  12. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
  13. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA1
Uniprot ID:
P02708
Molecular Weight:
54545.235 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNB1
Uniprot ID:
P11230
Molecular Weight:
56697.9 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Acetylcholine-activated cation-selective channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRND
Uniprot ID:
Q07001
Molecular Weight:
58894.55 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNG
Uniprot ID:
P07510
Molecular Weight:
57882.8 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Cation transmembrane transporter activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNE
Uniprot ID:
Q04844
Molecular Weight:
54696.54 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA3
Uniprot ID:
P32297
Molecular Weight:
57479.54 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA5
Uniprot ID:
P30532
Molecular Weight:
53053.965 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Acetylcholine-activated cation-selective channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA6
Uniprot ID:
Q15825
Molecular Weight:
56897.745 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Calcium channel activity
Specific Function:
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding induces a conformation change that leads to the opening of an ion-conducting channel across the plasma membrane (PubMed:11752216, PubMed:25282151). The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the ...
Gene Name:
CHRNA9
Uniprot ID:
Q9UGM1
Molecular Weight:
54806.63 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Receptor binding
Specific Function:
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes t...
Gene Name:
CHRNA10
Uniprot ID:
Q9GZZ6
Molecular Weight:
49704.295 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodiun ions.
Gene Name:
CHRNB2
Uniprot ID:
P17787
Molecular Weight:
57018.575 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNB3
Uniprot ID:
Q05901
Molecular Weight:
52728.215 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNB4
Uniprot ID:
P30926
Molecular Weight:
56378.985 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Svoboda Z, Kvetina J, Kunesova G, Herink J, Bajgar J, Bartosova L, Zivny P, Palicka V: Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues. Neuro Endocrinol Lett. 2006 Dec;27 Suppl 2:183-6. [PubMed:17159811 ]
  2. Giacobini E: Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging. 2001;18(12):891-8. [PubMed:11888344 ]
  3. Wilkinson DG: Galantamine: a new treatment for Alzheimer's disease. Expert Rev Neurother. 2001 Nov;1(2):153-9. doi: 10.1586/14737175.1.2.153. [PubMed:19811027 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 02:26